One of the advantages of the anti-VEGFR (anti-angiogenic) drugs is that they can be prescribed for wider groups of CRC patients as they have more diverse biomarkers and predictive factors of response compared to the anti-EGFR drugs [6,7]. Here, EGFR is linked to colorectal carcinoma.